Discussion of “A Hybrid Phase I‐II/III Clinical Trial Design Allowing Dose Re‐Optimization in Phase III” by Andrew G. Chapple and Peter F. Thall

Eric S. Leifer and Nancy L. Geller

Biometrics, 2019, vol. 75, issue 2, 382-384

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/biom.12993

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:75:y:2019:i:2:p:382-384

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X

Access Statistics for this article

More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().